|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Xcyte Therapies, Inc. Announces Full-Year And Fourth-Quarter 2004 Financial Results
10/19/2005 5:13:11 PM
SEATTLE--(BUSINESS WIRE)--March 31, 2005--Xcyte Therapies, Inc. (Xcyte, the "Company") (Nasdaq:XCYT) reported today a net loss applicable to common shareholders of $48.6 million, or $3.90 per basic and diluted share, for the year ended December 31, 2004, compared with $18.5 million, or $12.40 per basic and diluted share, for the year ended December 31, 2003. Revenue during 2004 totaled $62,000, compared with $170,000 during 2003. Total operating expenses were $26.6 million for the year ended December 31, 2004, compared with $18.0 million for the year-earlier period. Research and development expenses were $19.7 million and $13.7 million in 2004 and 2003, respectively, while general and administrative expenses were $6.9 million and $4.3 million in the same periods.
|
|
|
|
|
|
|
|
|
|
|